New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
18:55 EDTJAZZJazz Pharmaceuticals presents data from Erwinaze safety trial
Jazz Pharmaceuticals announced that data from the largest safety trial to date of patients treated with Erwinaze have been presented at the American Society of Hematology Annual Meeting and Exposition. The poster presentation is based on results of a compassionate use protocol in patients who received Erwinaze as part of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia who developed a hypersensitivity to E.coli-derived asparaginase. The poster summarizes the safety results in 940 patients at participating U.S. oncology treatment centers between February 2006 and November 2011, when Erwinaze was available under a compassionate use protocol prior to its approval by the FDA in November 2011. The trial includes additional follow up data that further describe the incidence of adverse events associated with Erwinaze treatment, which are consistent with the known safety profile of Erwinaze.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
14:42 EDTJAZZJazz Pharmaceuticals management to meet with Canaccord
Group dinner to be held in New York on November 30 hosted by Canaccord.
07:33 EDTJAZZMylan launches Clozapine Orally Disintegrating Tablets in the U.S.
Mylan (MYL) announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo (JAZZ). Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
November 18, 2015
08:28 EDTJAZZLeerink to hold a bus tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use